These unremarkable remarks raise a number of questions. First, is it a necessary truth that
disposi? tions have causal bases; or is it only a contingent truth for dispositions like fragility, …

… , prior or expert opinion to be included in the analysis, and hierarchical descriptions of both
local-scale and global features of the model. This chapter aims to introduce the prior … prior …

Background The programmed death 1 (PD-1) receptor is a negative regulator of T-cell
effector mechanisms that limits immune responses against cancer. We tested the anti–PD-1 …

… Patients were ineligible if they had received any prior treatment for metastatic disease.
Patients who received prior adjuvant therapy were not excluded. Concomitant treatment with …

… Safety was consistent with results of prior BV trials. … or unavailable); prior adjuvant or
neoadjuvant chemotherapy within … fraction ≥ 50% and no prior history of adjuvant Anthra …

… For instance, in the mixture case, if both prior and likelihood are invariant with respect to
the labels of the components, all marginals (in the components) are the same, all posterior …

… In univariate analysis, characteristics prior to admission significantly associated with the …
In multivariable analyses with covariates prior to admission, only BMI remained positively …

… prior adjuvant chemotherapy, and all had received prior chemotherapy for metastatic disease;
32% had one prior and 68% had two prior … Most had received both prior anthracycline and …

… We show that CSR is initiated over the first few days in a primary response and prior to EF
and GC commitment, ceasing soon after B cells become GC cells and SHM commences. We …

… Consistent with the results of prior individual studies of … We observed an apparent plateau
in the survival curve regardless of prior … However, as for the analyses by prior therapy, these …